Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2005-11-09
2008-08-05
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Reexamination Certificate
active
07408022
ABSTRACT:
The invention provides cell permeable peptides and peptide agents that inhibit anti-apoptotic processes in cancer cells to promote tumor cell death, as well as a method for providing therapeutic treatment for cancer. The composition may be delivered in conjunction with a conventional chemotherapeutic agent to provide a synergistic effect that significantly increases the effectiveness of the chemotherapeutic agent to destroy cancer cells. The invention also provides kits or systems for cancer therapy, comprising at least one peptide agent for inhibiting the anti-apoptotic effects of NF-kB and at least one chemotherapeutic agent for stimulating the cellular apoptotic pathway.
REFERENCES:
patent: 2002/0169121 (2002-11-01), Ronai
patent: 2003/0095979 (2003-05-01), Mattner et al.
Freshney, Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York.
Dermer, Bio/Technology, 1994, 12:320.
Zips, In Vivo, 2005, 19:1-7.
Gura, Science, 1997, 278:1041-1042.
Jain, Sci. Am., 1994, 271:58-65.
Curti, Crit. Rev. in Oncology/Hematology, 1993, 14:29-39.
Lin et al., Inhibition of Nuclear Translocation of Transcription Factor NF-kB by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence,J. Biol. Chem., Jun. 1995, vol. 270, No. 24, pp. 14255-14258.
Sumitomo, M. et al., An Essential Role for Nuclear Factor Kappa B in preventing TNF-α-induced Cell Death in Prostate Cancer Cells,J. Urol., Feb. 1999, vol. 161, pp. 674-679.
Poulaki, V. et al., Constitutive Nuclear Factor- κB Activity is Crucial for Human Retinoblastoma Cell Viability, Am. J. Pathol., Dec. 2002, vol. 161, No. 6, pp. 2229-2240.
Garg, A. and Aggarwal, BB., Nuclear Transcription Factor κ-B as a Target for Cancer Drug Development,Leukemia, 2002, vol. 16, pp. 1053-1068.
Baldwin, A.S., Control of Oncogenesis and Cancer Therapy Resistance by the Transcription Factor NF-κB,J. Clin. Invest., Feb. 2001, vol. 207, No. 3, pp. 241-246.
Yamamoto, Y. and Gaynor, R., Therapeutic Potential of Inhibition of the NF- κB Pathway in the Treatment of Inflammation and Cancer,J. Clin Invest., Jan. 2001, vol. 107, No. 2, pp. 135-142.
Mitsiades, N., Biologic Sequelae of Nuclear Factor- κB Blockade in Multiple Myeloma: Therapeutic Applications,Blood, Jun. 1, 2002, vol. 99, No. 11, pp. 4079-4086.
Hawiger, J., Noninvasive Intracellular Delivery of Functional Peptides and Proteins,Curr. Opin. Chem. Biol., 1999, vol. 3, pp. 89-94.
Shukla, S. and Gupta, S., Suppression of Constitutive and Tumor Necrosis Factor α-Induced Nuclear Factor (NF)- κB Activation and Induction of Apoptosis by Apigenin in Human Prostate Carcinoma PC-3 Cells: Correlation with Down-Regulation of NF- κB-Responsive Genes,Clin. Cancer Res., May 1, 2004, vol. 10, pp. 3169-3178.
Duffey, D., et al., Expression of a Dominant-Negative Mutant Inhibitor- κBα of Nuclear Factor- κB in Human Head and Neck Squamous Cell Carcinoma Inhibits Survival, Proinflammatory Cytokine Expression, and Tumor Growth in Vivo,Cancer Res., Jul. 15, 1999, vol. 59, pp. 3468-3474.
Budu Claudia
Lin Yao-Zhong
Celtek Bioscience, LLC
Halvorson Mark
Russell Donna
Yu Misook
LandOfFree
Composition and method for increasing apoptosis in cancer cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for increasing apoptosis in cancer cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for increasing apoptosis in cancer cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4003288